Document Detail

Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model.
MedLine Citation:
PMID:  15821839     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The functional impact of cellular transplantation and the potential role of the addition of angiogenic factors for survival of engrafts remain controversial. METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Group 1 (n = 12) received cells plus VEGF protein (100 ng), group 2 (n = 12) received cells without VEGF, group 3 (n = 10) received VEGF without cells, and group 4 (n = 12) received pure culture medium. Cardiac function was then assessed by transthoracic two-dimensional echocardiography and Langendorff perfusion system. In situ hybridization for Y chromosomes of transplanted cells, detection of BrDU-labeled cells, and platelet/endothelial cell adhesion molecule-1 (PECAM-1) staining for endothelial cells was performed. RESULTS: Echocardiography revealed smaller end-diastolic left ventricular dimensions in transplanted hearts in group 1 (0.83 +/- 0.13 cm 4 weeks after coronary occlusion before transplantation and 0.69 +/- 0.14 cm 2 months after transplantation, P < .05) and in group 2 (0.88 +/- 0.09 cm after coronary occlusion before transplantation and 0.76 +/- 0.08 cm 2 months after transplant), and increases in fractional shortening (34.2% +/- 8.53% before transplant and 45.3% +/- 10.9% after [P < .05] in group 1; 26.9% +/- 6.02% before transplant and 37.15% +/-8.08% after [P < .005] in group 2), whereas groups 3 and 4 showed a decrease in fractional shortening. Transplanted hearts developed higher pressures at rest (group 1, 96.8 +/- 20.8 mm Hg; group 2, 98.6 +/- 21.9 mm Hg) compared with controls (group 4, 70.9 +/- 25 mm Hg) (P < .05) and during inotropic stimulation (group 1, 111 +/- 19.5 mm Hg and group 2, 113.3 +/- 32.6 vs group 4, 80.7 +/- 31.6 mm Hg, P < .05). Histologic analysis demonstrated the presence of transplanted cells in border zones of infarcted host myocardium with neovascularization in all transplanted hearts. CONCLUSION: Transplantation of fetal cardiomyocytes results in improvement of left ventricular function. The addition of VEGF does not contribute to further improvement of left ventricular function and angiogenesis in the present model.
Alexander Schuh; Sebastian Breuer; Raja Al Dashti; Nasir Sulemanjee; Peter Hanrath; Christian Weber; Barry F Uretsky; Ernst R Schwarz
Related Documents :
3305829 - Bridging circulatory support before heart transplant without invasion of the mediastinum.
8572789 - Safety of repeat aprotinin administration for lvad recipients undergoing cardiac transp...
2597549 - Extended clinical support with an implantable left ventricular assist device.
15223449 - Video-assisted thoracoscopic transplantation of myoblasts into the heart.
2803059 - Clinical total artificial heart bridging: viennese strategy and experiences.
7513899 - Simple device for continuous measurement of fluorescent anions and cations in the rat k...
384859 - Hyperlipidemia after renal transplantation: natural history and pathophysiology.
8672979 - Renal cell carcinoma arising from the free wall of a renal cyst.
23139689 - Risk factors for renal failure in patients with lupus nephritis: data from the spanish ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  10     ISSN:  1074-2484     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-04-11     Completed Date:  2005-06-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  55-66     Citation Subset:  IM    
Medical Clinic, Department of Molecular Cardiovascular Research, RWTH University Hospital, Aachen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cells, Cultured
Disease Models, Animal
Myocardial Infarction / therapy*,  ultrasonography
Myocytes, Cardiac / cytology,  transplantation*
Neovascularization, Physiologic
Vascular Endothelial Growth Factor A / administration & dosage*
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of methods for the measurement of low-density lipoprotein cholesterol.
Next Document:  The influence of extracellular acidosis on the effect of IKr blockers.